Brief: Gain Announces Completion Of Dosing In Multiple Ascending Dose Of Phase 1 Study Of GT-02287, Therapy For Parkinson’s Disease

Gain Therapeutics

09/07/2024 12:26

July 9 (Reuters) - Gain Therapeutics Inc  GANX.O :
    * GAIN THERAPEUTICS ANNOUNCES THE COMPLETION OF DOSING IN
THE
MULTIPLE ASCENDING DOSE (MAD) OF THE PHASE 1 STUDY OF GT-02287,
A NOVEL SMALL MOLECULE THERAPY FOR PARKINSON’S DISEASE
    * GAIN THERAPEUTICS INC - GT-02287 WELL TOLERATED WITH NO
SERIOUS
ADVERSE EVENTS
    * GAIN THERAPEUTICS INC - TOPLINE DATA TO BE PRESENTED
MID-AUGUST
    * GAIN THERAPEUTICS INC - GT-02287 TRIAL IN PARKINSON'S
DISEASE
PATIENTS IN Q4 2024
    * GAIN THERAPEUTICS INC - NO DISCONTINUATIONS OR SERIOUS
ADVERSE
EVENTS REPORTED

Source text for Eikon:  ID:nGNXc4Y0cN 
Further company coverage:  GANX.O 

 ((Reuters.Briefs@thomsonreuters.com;))